ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Second Heart Assist Announces Completion of Series D Financing

Mission Viejo, California, United States - 02-28-2023 (PR Distribution™) -

Salt Lake City, Utah –Second Heart Assist, Inc. a clinical stage medical device company, today announced completion of a $4.41 million Series D financing led by Vestech Securities LLC.  This brings total paid in cash capital to over $15.4 million.

Second Heart Assist, Inc. will use new funding to continue to advance testing of both its 1st generation Whisper TM catheter based circulatory assist pump and Freedom TM its 2nd generation wireless powered implant. Both products are based on the company’s patented aortic stent platform technology. 

The company is about to embark on a second round of clinical studies this time in treating patients with cardio-renal syndrome heart failure. Details of this new OUS study will be announced shortly. 

December 24th, 2022 the company received a Letter of Allowance from the United States Patent and Trademark office on the issuance of 21 new patent claims.  These newly issued patent claims add to over 100 previous patent claims that company has had issued or exclusively licensed.  The company believes it has the pre-eminent IP estate in the sector especially when it comes to a stable wireless powered implant that also maintains aortic wall pulsatility. 

"The Second Heart Assist, Inc. device pipeline is poised to provide valuable new tools to physicians managing patients in cardio-renal syndrome and heart failure.  These patients are a great challenge especially when diuretic resistant. New tools are certainly needed to provide better management.” said Dr. Leslie Miller, M.D Chief Medical Officer. 

“The entire Second Heart team is highly focused on completing our planned cardio-renal syndrome heart failure pilot study in North America and preparing for a subsequent pivotal Phase II multi-center study including full cGMP compliance in manufacturing.  This new funding should permit us to reach these goals in 2023.”  stated jointly Howard J. Leonhardt, Executive Chairman & CEO and Jeff Donofrio President 

About Second Heart Assist, Inc.:

Incorporated in 2017 Second Heart Assist, Inc. is focused on developing a pipeline of next generation percutaneous (non surgical) placed circulatory assist devices.  See www.secondheartinc.com for more information.  The Second Heart development project began within the Leonhardt's Launchpads innovation and startup launch accelerator program.

Contact:

Howard J. Leonhardt 
Executive Chairman & CEO
hleonhardt@secondheartinc.com 

Media Contacts:

Company Name: Second Heart Assist, Inc.
Full Name: Howard J. Leonhardt
Phone: (424) 291-2133
Email Address: Send Email
Website: http://www.secondheartinc.com

For the original news story, please visit https://www.prdistribution.com/news/second-heart-assist-announces-completion-of-series-d-financing/9565322.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.